If we take some recent examples of other Biotechs on the ASX which have ODD and have or plan for FDA accelerated approval, each have already signed up one or two partnership deals ahead of anticipated approval. That way, all the prepatory work around distribution of the drug occurs in parallel and ready for market launch if accelerated approval comes through. I think it's reasonable to assume that PAA will aim for a similar approach if buyout does not occur. 
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-873
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
-0.005(2.33%) |
Mkt cap ! $93.45M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.5¢ | 21.0¢ | $85.73K | 407.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 53482 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 278844 | 4 |
View Market Depth
| Last trade - 15.15pm 19/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |